- Home
- JKHY vs MDGL Comparison
JKHY vs MDGL Comparison
Compare JKHY & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKHY | MDGL |
|---|---|---|
| Founded | 1976 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 11.1B |
| IPO Year | 2000 | 2005 |
Fundamental Metrics
Financial Performance| Metric | JKHY | MDGL |
|---|---|---|
| Price | $133.16 | $486.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $197.25 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 1.4M | 284.2K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | 19.31 | ★ 41.32 |
| EPS | ★ 5.41 | N/A |
| Revenue | ★ $1,536,603,000.00 | $180,133,000.00 |
| Revenue This Year | $8.03 | $58.39 |
| Revenue Next Year | $6.39 | $48.55 |
| P/E Ratio | $24.61 | ★ N/A |
| Revenue Growth | ★ 7.37 | N/A |
| 52 Week Low | $131.39 | $275.00 |
| 52 Week High | $193.39 | $615.00 |
Technical Indicators
Market Signals| Indicator | JKHY | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 33.92 | 42.66 |
| Support Level | $132.36 | $461.99 |
| Resistance Level | $158.39 | $502.97 |
| Average True Range (ATR) | 4.27 | 21.60 |
| MACD | 0.05 | -6.10 |
| Stochastic Oscillator | 10.81 | 37.40 |
Price Performance
Historical ComparisonAbout JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, including electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.